The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.
Study Type
EXPANDED_ACCESS
Fosmanogepix solution for infusion, 20 mg/mL for intravenous administration
Fosmanogepix 400 mg tablets for oral administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.